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ABSTRACT
Objective: To present an update on the diagnosis and treatment of hypoparathyroidism based on 
the most recent scientific evidence. Materials and methods: The Department of Bone and Mineral 
Metabolism of the Sociedade Brasileira de Endocrinologia e Metabologia (SBEM; Brazilian Society 
of Endocrinology and Metabolism) was invited to prepare a document following the rules set by 
the Guidelines Program of the Associação Médica Brasileira (AMB; Brazilian Medical Association). 
Relevant papers were retrieved from the databases MEDLINE/PubMed, LILACS, and SciELO, and the 
evidence derived from each article was classified into recommendation levels according to scientific 
strength and study type. Conclusion: An update on the recent scientific literature addressing 
hypoparathyroidism is presented to serve as a basis for the diagnosis and treatment of this condition 
in Brazil. Arch Endocrinol Metab. 2018;62(1):106-24
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INTRODUCTION
S erum calcium concentration is maintained within a narrow physiological range by complex controlling 
mechanisms involving the parathyroid hormone 
(PTH), active vitamin D (1,25(OH)2D), and calcium 
sensor receptors (CaSRs) acting in renal, intestinal, 
parathyroid, and bone tissues to maintain mineral 
homeostasis. When these homeostatic mechanisms fail 
or are not fully compensated, hypocalcemia occurs (1).
Inappropriately low (insufficient) circulating 
PTH levels, which in adults occurs mainly after 
thyroid surgery, is the most common cause of 
hypocalcemia. Current standard treatment of low 
PTH levels comprising vitamin D analogs and calcium 
supplementation is challenging as it does not involve 
replacing the missing hormone (2).
Over the past ten years, we have gained a greater 
understanding of hypoparathyroidism regarding its 
epidemiology, genetics, associated skeletal disease, and 
therapies. A major therapeutic challenge in hypocalcemia 
is effectively balancing calcium levels while avoiding 
hypercalciuria and other complications (3).
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This document is a result of efforts by the 
Department of Bone Metabolism of the Sociedade 
Brasileira de Endocrinologia e Metabologia (SBEM; 
Brazilian Society of Endocrinology and Metabolism) 
for the development of recommendations based 
on the current evidence available in the scientific 
literature regarding the diagnosis and treatment of 
hypoparathyroidism. The objective of this document is 
to answer routine questions and serve as a guideline for 
endocrinologists and clinicians in Brazil. 
MATERIALS AND METHODS
We elaborated this guideline motivated by SBEM’s 
Practical Guidelines Program. The model applied to 
this document followed the Guidelines Program of the 
Associação Médica Brasileira (AMB; Brazilian Medical 
Association) and Conselho Federal de Medicina (CFM; 
Federal Medical Council). After selecting collaborators 
with a significant role and relevant publications in the 
area of hypoparathyroidism, we elaborated clinical 
questions for discussion. We searched the databases 
MEDLINE/PubMed and SciELO/LILACS for 
relevant publications, and categorized each publication 
according to the level of evidence, as recommended 
by the Oxford Centre for Evidence-Based Medicine. 
These recommendations evaluate the study design and 
consider the best available evidence for each question to 
attribute a recommendation level or evidence strength 
to each article (4,5). In this document, we report the 
levels of recommendation and evidence as:
A:  experimental or observational studies with 
consistent results.
B:  experimental or observational studies with less 
consistent results.
C:  case reports (uncontrolled studies).
D:  opinion is lacking critical evaluation or is based 
on guidelines, physiological studies, or animal 
models.
ETIOLOGY
1.  What are the causes and differential diagnoses of 
hypocalcemia?
Decreases in serum ionized calcium are recognized 
by CaSRs in the parathyroid glands, eliciting PTH 
release from preexisting pools and stimulating PTH 
production and secretion. Serum calcium levels are 
then restored by PTH-mediated decreases in urinary 
calcium excretion, and increases in bone resorption and 
intestinal calcium absorption, the later in association 
with increased 1,25(OH)2D (calcitriol) synthesis in the 
renal tubules. Thus, the causes of hypocalcemia may 
be divided into those associated with PTH deficiency 
or resistance (addressed separately), and those not 
directly associated with hypoparathyroidism, as listed in 
Table 1 (6-9).
Although hypoalbuminemia is the most common 
cause of low serum total calcium levels, it has no 
effect on the ionized calcium fraction and, therefore, 
no clinical significance. Thus, measurement of 
serum albumin is always recommended during the 
investigation of hypocalcemia, along with correction of 
the total calcium values, which is achieved by adding 
0.8 mg/dL to the total calcium level for each 1.0 g/dL 
decrease in albumin below 4.0 g/dL or by the formula: 
Calcium corrected = Calcium measured + [(4.0 - 
albumin) x 0.8] (6-9). 
Severe hypomagnesemia decreases PTH secretion 
and increases resistance to PTH effects in bone and 
kidney. The occurrence of hypomagnesemia should be 
considered in all patients with hypocalcemia and low or 
inappropriately normal PTH levels (6-9).
Severe calcium and/or vitamin D deficiency could 
be associated with hypocalcemia and lead to secondary 
hyperparathyroidism. Measurement of plasma 
25-hydroxyvitamin D [25(OH)D], the main vitamin D 
metabolite stored in the body, is recommended. The 
active metabolite of this vitamin [1,25(OH)2D] has a 
short plasma half-life and does not reflect the vitamin D 
status (6-14).
In acute pancreatitis, the action of pancreatic 
lipase generates free fatty acids that avidly chelate the 
insoluble calcium salts present in the pancreas, resulting 
in calcium deposition in the retroperitoneum (7).
In acute hyperphosphatemia, phosphate binds 
avidly to calcium leading to calcium deposition, mostly 
in bone but also in extraskeletal tissues. Hypocalcemia 
is commonly found in patients with chronic kidney 
disease in association with low 1,25(OH)2D levels and 
secondary hyperparathyroidism (15).
The hungry bone syndrome may occur after 
surgical cure of severe hyperparathyroidism, leading 
to hypocalcemia and hypophosphatemia due to a rapid 
increase in skeletal mineralization. Hypocalcemia is 
directly associated with the severity of bone disease and 
concomitant vitamin D deficiency (16).
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Intravenous bisphosphonates (17) and subcutaneous 
denosumab (18), potent antiresorptive agents used to 
treat osteoporosis, may lead to clinical hypocalcemia, 
mainly in vitamin D deficient patients. This side effect 
of antiresorptive agents is most commonly seen in high 
bone turnover states such as Paget’s disease of bone. 
Several other drugs may aggravate hypocalcemia 
by acting through diverse mechanisms, and their 
concomitant use should be evaluated in patients with 
low calcium levels. Some anticonvulsants accelerate the 
breakdown of vitamin D, limiting bone mineralization. 
Proton pump inhibitors and H2 blockers reduce the 
production of gastric acid, interfering with calcium 
absorption. Loop diuretics and glucocorticoids induce 
hypercalciuria; glucocorticoids also have detrimental 
effects in the intestinal action of vitamin D. Antiviral 
drugs have also been associated with a negative impact 
on calcium, vitamin D, and bone metabolism. A review 
of the subject by Liamis and cols. is recommended (19). 
Highlights SBEM: In normal conditions, about 50% 
of the total calcium circulates bound to albumin. Low 
albumin concentrations may inaccurately indicate 
hypocalcemia, but the ionized calcium fraction is 
normal. Thus, total calcium concentration should 
always be corrected by albumin level during the 
investigation of hypocalcemia (A). 
2. What are the causes of hypoparathyroidism? 
From a functional point of view, hypoparathyroidism 
arises from an inability of the parathyroid glands 
in secreting PTH and/or impaired PTH action, 
directly impacting the homeostasis of calcium 
and phosphorus (Table 2). Hypoparathyroidism 
resulting from peripheral resistance to PTH action 
is known as pseudohypoparathyroidism. Thus, the 
term “hypoparathyroidism” is commonly reserved to 
Table 1. Causes of hypocalcemia other than hypoparathyroidism and pseudohypoparathyroidism
Total calcium Ionic calcium PTH Symptoms  of hypocalcemia
Bone 
manifestations Associated diseases
Hypoalbuminemia Low Normal Normal Absent None Liver cirrhosis, nephrotic syndrome, 
burn, malnutrition, sepsis
Hypomagnesemia Low Low Variable Variable None Diuretics, chronic diarrhea,   small 
bowel bypass or resection 
Calcium deficiency Low Low High Variable Rickets/osteomalacia Severe malnutrition, Roux-en-Y 
gastric bypass (RYGB)
Vitamin D deficiency Low Low High Variable Rickets/osteomalacia 
increased resorption 
(decreased density)
Decreased sun exposure, obesity, 
dark skin, RYGB, aging, severe 
malnutrition, celiac disease, 
pancreatic diseases, steatorrhea, 
antiepileptic drugs
Hyperphosphatemia (acute) Low Low Variable Variable Dependent on the 
etiology
Phosphate-containing enemas, renal 
failure, intense tissue breakdown 
(rhabdomyolysis or tumor lysis)
Chronic kidney disease 
(CKD) and GFR  
< 30 mL/min/1.73 m2
Low Variable High Variable Hyperparathyroidism 
(eventual low 
turnover)
Severe hypertension, diabetes 
mellitus, and others
Hungry bone syndrome Low Low Variable Moderate/
severe
Hyperparathyroidism Surgical cure of hyperparathyroidism 
(primary or secondary to CKD)
Drugs: 
Antiresorptives 
(bisphosphonates, 
denosumab), calcimimetics 
(cinacalcet), calcium 
chelators (EDTA, citrate, 
foscarnet), antiepileptics 
(phenytoin, phenobarbital, 
carbamazepine), proton 
pump inhibitors, loop 
diuretics, chemotherapeutic 
drugs
Low Low Variable Variable Dependent on the 
etiology
Osteoporosis, primary or secondary 
hyperparathyroidism, blood 
transfusion, epilepsy, peptic ulcer, 
neoplasias, etc.
Acute pancreatitis Low Low High Variable None Alcohol abuse, gallbladder stones
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describe a situation in which the parathyroid glands are 
unable of properly producing PTH (A) (1-3,20).
2.1. Causes of hypoparathyroidism
The main cause of hypoparathyroidism is the surgical 
destruction of the parathyroids (A). Autoimmunity 
is considered the second most frequent etiology of 
hypoparathyroidism (1,2,21-23). Rare causes of 
hypoparathyroidism, such as parathyroid destruction 
by neoplastic infiltration or heavy metals, irradiation, 
radioiodine therapy, Riedel’s thyroiditis and genetic 
diseases affecting the development of the parathyroids 
and/or the production of PTH are listed in Table 2. 
Hypoparathyroidism may also result from deregulation 
of PTH secretion secondary to disorders of magnesium 
homeostasis or abnormal activation of CaSRs due to a 
genetic or autoimmune cause (23).
2.1.1. Postsurgical hypoparathyroidism
Surgical manipulation of the anterior cervical region 
is the most frequent cause of hypoparathyroidism, 
corresponding to 75% of the cases of the acquired form 
of the disease (A) (2,22-24). The destruction of the 
parathyroids may occur due to an aggressive surgical 
treatment of cervical cancer or may be accidental as a 
result of truncal ligation of the inferior thyroid arteries 
or inadvertent removal of the parathyroids (25-27). 
Relevant aspects of surgical-related hypoparathyroidism 
will be discussed separately in Section 4.
2.1.2. Autoimmune hypoparathyroidism 
Autoimmune aggression to the parathyroids is 
considered the second most common cause of 
hypoparathyroidism in adults (A) and may occur as an 
isolated endocrinopathy or as part of the autoimmune 
polyglandular syndrome type 1 (APECED) (2,22). 
Isolated autoimmune hypoparathyroidism has been 
related to antiparathyroid and anti-CaSR antibodies, 
but the pathogenic role of these antibodies is still 
poorly characterized. The prevalence of antiparathyroid 
and anti-CaSR antibody positivity in individuals with 
suspected autoimmune hypoparathyroidism is variable 
(between 25 to 40%), and the measurement of these 
antibodies is generally limited to research studies 
(2,28). In clinical practice, the presence of other 
autoimmune manifestations helps the identification of 
autoimmune hypoparathyroidism in individuals who 
develop nonsurgical hypoparathyroidism (D). The 
autoimmune polyglandular syndrome type 1 is a rare 
autosomal recessive disease caused by mutations in the 
AIRE gene, characterized mainly by mucocutaneous 
candidiasis, hypoparathyroidism, and adrenal 
insufficiency; several other autoimmune manifestations 
may also occur (C) (29). 
2.2.  Hypoparathyroidism due to deregulation of PTH 
secretion 
Changes in magnesemia may lead to functional 
hypoparathyroidism (2,21). Magnesium participates in 
Table 2. Causes of hypoparathyroidism
Hypoparathyroidism due to PTH 
deficiency
Parathyroid destruction
Following cervical surgery
Cervical radiotherapy or radioiodine therapy
Autoimmune: isolated or associated with polyglandular disease [AIRE]
Parathyroid infiltration by neoplastic, granulomatous, or storage diseases 
(Wilson’s disease and hemochromatosis)
Riedel’s thyroiditis
Genetic diseases affecting parathyroid 
development and/or PTH production 
Isolated hypoparathyroidism [PTH, GCM2, SOX3]
Genetic syndromes associated with hypoparathyroidism (e.g. DiGeorge, 
CHARGE, Kenny-Caffey, Sanjad-Sakati, HDR, etc.) [TBX1, NEBL, GATA3, 
TBCE, FAM111A, CHD7, SEMA3E]
Mitochondrial diseases
Regulation change in PTH secretion
Autosomal dominant hypocalcemia type 1 [CASR] and type 2 [GNAS11]
Activating anti-CASR antibodies 
Chronic hypomagnesemia and hypermagnesemia
Functional hypoparathyroidism due to 
peripheral resistance to PTH action
Pseudohypoparathyroidism Genetic defects in PTH post-receptor signaling [GNAS, STX16, NESP55, 
PRKAR1A, PDE4D]
Genes associated with hypoparathyroidism are shown in square brackets. Compiled from (23,31,32).
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both processes of PTH secretion and action through 
the adenylcyclase system. Thus, conditions of chronic 
magnesium depletion (chronic diarrhea, alcoholism, 
poorly controlled diabetes mellitus, and chronic 
use of proton pump inhibitors and diuretics) cause 
hypocalcemia with inappropriately normal or overtly low 
PTH levels. On the other hand, acute hypermagnesemia 
(due to the excessive parenteral administration or 
renal insufficiency) also leads to hypocalcemia since 
magnesium may activate CaSRs and suppress PTH 
secretion (22). Rare genetic defects of factors involved 
in the homeostasis of magnesium (TRMP6, CLND16, 
CLDN19) may also cause hypoparathyroidism (22). 
Therefore, serum magnesium levels must be determined 
upon evaluation of hypocalcemia, to exclude functional 
hypoparathyroidism (A). PTH secretion may also be 
deregulated by anti-CaSR antibodies activating the 
CaSR receptor by mimicking calcium and inhibiting 
the secretion of this hormone; this is a rare cause of 
hypoparathyroidism (28).
2.2.2 Causes of pseudohypoparathyroidism
Peripheral resistance to PTH action resulting 
in functional hypoparathyroidism is known as 
pseudohypoparathyroidism. This condition is caused 
by genetic defects in postreceptor PTH signaling and 
is characterized in laboratory tests by hypocalcemia and 
hyperphosphatemia in the presence of elevated PTH 
levels in patients with normal renal function (A). In 
pseudohypoparathyroidism, the production of PTH by 
the parathyroids is normal, and the biochemical disorder 
resulting from hormonal resistance (hypocalcemia 
and hyperphosphatemia) stimulates increased PTH 
production. The main genetic defects causing 
pseudohypoparathyroidism are inactivating mutations 
of the alpha subunit of the stimulatory G protein, 
coded by the GNAS gene, which in physiological 
conditions acts by coupling to the PTH receptor and 
propagating the stimulation arising from the binding 
of the hormone to the receptor (A) (30). Thus, in 
pseudohypoparathyroidism, defects in the GNAS gene 
interfere with PTH signaling in peripheral target tissues, 
particularly in the kidneys. Other molecular defects 
(for example, modification in GNAS methylation) or 
defects in other mediators of PTH signaling in target 
tissues (for example, PRKAR1A) may also cause 
pseudohypoparathyroidism (A) (23). The diagnosis 
and management of pseudohypoparathyroidism are 
beyond the scope of this article.
Highlights SBEM: In patients without a history 
of conditions leading to parathyroid destruction, 
other causes of hypocalcemia must be considered. 
Clinical and laboratory evaluation of these patients 
is fundamental since, in most cases, it is not difficult 
to identify the cause of the hypocalcemia (A), 
although differentiating autoimmune from idiopathic 
hypoparathyroidism may be clinically challenging.
EPIDEMIOLOGY 
3. What is the prevalence of hypoparathyroidism?
Hypoparathyroidism is a rare disorder with an 
estimated prevalence of 0.25 per 1,000 individuals 
(B) (33,34). Most patients with hypoparathyroidism 
had their parathyroids incidentally removed or injured 
during thyroid surgery (35). Transient postsurgical 
hypoparathyroidism is common, due to functional 
parathyroid impairment after acute manipulation, with 
subsequent spontaneous recovery. However, it may, 
more rarely, be definitive (C) (22). Despite literature 
reports of recoveries occurring more than six months 
after surgery, hypoparathyroidism is considered 
definitive when lasting more than six months from the 
surgical event (D) (2,3,20,36). 
The actual prevalence of postsurgical 
hypoparathyroidism is probably underestimated, due to 
lack of clear definitions, inappropriate follow-up, conflicts 
of interest in reports of individual series, and different 
strategies in calcium and vitamin D supplementation, 
among other causes. Thus, the prevalence of transient 
hypoparathyroidism varies widely from 3% to 52%, 
while that of definitive hypoparathyroidism ranges 
from 0.4% to 13% (24,37-44). Since postsurgical 
hypoparathyroidism is due to direct parathyroid injury, 
treatment with total thyroidectomy is associated with 
increased rates of hypoparathyroidism when compared 
with partial thyroid surgeries (subtotal thyroidectomy 
and hemithyroidectomy) (Table 3). On the other hand, 
these rates are even higher with central compartment 
(level VI) lymph node dissections and in thyroid and 
parathyroid reoperations, especially in parathyroid 
hyperplasia (B) (45,46). Although the Brazilian 
literature in this regard is scarce, the results of Brazilian 
studies are aligned with those described above (25,47-
52) (Table 3).
Co
py
rig
ht
©
 A
E&
M
 a
ll r
ig
ht
s r
es
er
ve
d.
111
Diagnosis and treatment of hypoparathyroidism
Arch Endocrinol Metab. 2018;62/1 
Table 3. Epidemiology of post-surgical hypoparathyroidism
Reference Author, year Country Prevalence of hypoparathyroidism Comments
27 Underbjerg and cols., 2013 Denmark 22/100,000 (general population) Data from 1988 to 2012
33 Powers and cols., 2013 USA 5.0% 120,000 surgeries in one year
35 Rosato and cols., 2004 Italy 1.7% 15,000 thyroidectomies with a 5-year follow-up
37 Youngwirth and cols., 2010 USA 0.74% 12% of patients had transient 
hypoparathyroidism, only 2 required calcitriol in 
the long term
38 Snyder and cols., 2013 USA 1.0% (for Graves’ disease) 
1.8% (for other types of hyperthyroidism)
0% (for other benign diseases)
780 total thyroidectomies for different reasons
39 Pelizzo and cols., 2014 Italy 3.3% 233 patients after a second thyroid surgery
40 Puzziello and cols., 2014 Italy 0.9% 2,631 thyroidectomies 
28.8% had transient hypocalcemia 
41 Ritter and cols., 2015 USA 1.9% 1,054 thyroidectomies
42 Wei and cols., 2014 China 0.9% (3/321) – autotransplantation 3.8% 
(6/156) – parathyroid glands preserved in place
477 thyroidectomies with (n = 321) and without 
(n = 156) parathyroid autotransplantation
43 Ito and cols., 2014 Japan 8% 154 completion thyroidectomies after a previous 
thyroidectomy 
44 Lorente-Poch and cols., 2015 Spain 4.6% 657 thyroidectomies, 1-year follow-up
45 Nawrot and cols., 2014 Poland 8.5% 401 thyroidectomies
46 Järhult and cols., 2012 Sweden 6% of the total thyroidectomies 265 thyroidectomies in patients with Graves’ 
disease
47 Dedivitis and cols., 2010 Brazil 6.6% 91 thyroidectomies, 6 patients had biochemical 
hypoparathyroidism after 1 month 
48 Accetta and cols., 2011 Brazil 0/66 – no case 66 thyroidectomies
49 Vanderlei and cols., 2012 Brazil 2.5% 40 thyroidectomies
50 Molinari and cols., 2015 Brazil 0.3% 3,411 thyroidectomies
51 Ywata de Carvalho and cols., 
2015
Brazil 11.8% of patients with central neck dissection
2.3% of patients without central neck dissection
Two different groups: total thyroidectomy with  
(n = 106) and without central neck dissection  
(n = 478)
52 Montenegro and cols., 2012 Brazil 28% 83 patients with hyperparathyroidism due to 
MEN-1/all with  parathyroid autotransplantation 
Highlights SBEM: There are no consistent data on 
the prevalence of permanent hypoparathyroidism after 
surgery. The risk of postsurgical hypoparathyroidism 
should be considered upon recommendation of 
thyroid/parathyroid surgeries, along with the extent 
of the procedures (C).
SURGICAL ASPECTS
4.  Is it possible to prevent postsurgical 
hypoparathyroidism?
Injury to the parathyroid glands during thyroid surgery 
may be due to direct tissue trauma (mechanical or 
thermal), injury to the vascular pedicle, inadvertent 
removal of the parathyroids during surgery, or even 
intentional removal of the glands for oncologic reasons 
(for example, presence of metastases in the central 
compartment, which upon resection could also remove 
the parathyroids from their location) (53,54). 
Maintaining intact parathyroids in place is the most 
important factor in preventing hypoparathyroidism 
(44,55). This requires from the surgeons a broad 
knowledge of the anatomy and embryology of 
the parathyroids, meticulous surgical technique, 
and command of parathyroid autotransplantation 
techniques in case the glands are removed (43,56,57). 
There is no standard and widely used technique 
in terms of handling of the parathyroids during 
thyroidectomy, but some aspects may be highlighted: 
ligation of the inferior thyroid artery branches should 
Co
py
rig
ht
©
 A
E&
M
 a
ll r
ig
ht
s r
es
er
ve
d.
112
Diagnosis and treatment of hypoparathyroidism
Arch Endocrinol Metab. 2018;62/1 
be performed as close as possible to the thyroid capsule 
to avoid vascular lesions; direct cauterization of the 
parathyroids or within millimeters from them must be 
avoided; careful dissection of the thyroid capsule should 
be performed, gently moving away the parathyroids 
without causing tissue or vascular trauma; when central 
compartment lymph node dissection is required (where 
the inferior parathyroids are at greater risk), start by 
identifying and maintaining the superior parathyroids 
intact and in place; inspect the thyroid after removal in 
search of parathyroids that may have been inadvertently 
resected. In this case, autotransplantation of small 
fragments of the removed parathyroid (approximately 
2 mm3) is recommended, followed by their implantation 
usually in the homolateral sternocleidomastoid muscle 
(43,56,57), although the actual effectiveness of this 
procedure has been questioned by several authors (B) 
(44,58).
There have been recent attempts at the development 
of auxiliary methods to identify the parathyroid 
glands during thyroidectomy, such as the injection 
of nanoparticles of carbon into the thyroid (59,60) 
and detection of the natural autofluorescence of the 
parathyroid with near-infrared imaging (61-63) or in 
association with methylene blue (64) or indocyanine 
green (65). In spite of these techniques improving 
the identification of the parathyroids, they have been 
unable to reduce the rates of hypoparathyroidism after 
total thyroidectomy (B) (66).
Highlights SBEM: The maintenance of intact 
parathyroids in place is the most important factor 
in preventing hypoparathyroidism. Extensive 
knowledge of anatomy and embryology, meticulous 
surgical technique, and command of parathyroid 
autotransplantation techniques may minimize the risk 
of hypoparathyroidism. To date, no technology for 
intraoperative identification of the parathyroids has 
proven effective in reducing the rates of permanent 
hypoparathyroidism (B).
5.  Is it possible to predict the risk of hypocalcemia 
after thyroidectomy?
Efforts have been directed toward the identification of 
patients at higher risk of developing hypocalcemia after 
thyroidectomy. These efforts were initially focused on 
protocols recommending serial blood sample collection 
for measurement of calcium levels (67-69) and, more 
recently, also include measurement of PTH levels 
(49,70-85). The literature describes several protocols 
for measurement of serum PTH levels (49,73,80,82), 
with variations in the time of blood collection, 
criteria for the diagnosis of hypocalcemia, number of 
collected blood samples, and different PTH cutoff 
levels. The decay of PTH levels in samples collected 
before and 1 hour after surgery has been associated 
with the occurrence of hypocalcemia (B) (49,83). A 
single postoperative measurement has also shown 
to correlate with the occurrence of hypocalcemia. 
Samples can be collected from the end of the surgery 
(49,70,71,78,79,81) till the first postoperative day (B) 
(72,76,84). None of these studies has guaranteed 100% 
accuracy with such measurements. Severe hypocalcemia 
is unlikely with a normal PTH value measured 
after surgery (75). Although the time period, PTH 
value, and ideal protocol have not been defined yet, 
perioperative PTH measurements appear to be useful in 
the postoperative management of patients undergoing 
thyroidectomy who later develop hypoparathyroidism. 
Highlights SBEM: The use of perioperative 
PTH values may be useful in predicting the risk of 
hypocalcemia in patients undergoing thyroidectomy. 
However, the protocol must be established according 
to the experience of each institution (B).
CLINICAL MANIFESTATIONS
6.  What are the acute and chronic clinical 
manifestations of hypocalcemia?
Hypocalcemia may be associated with several signs 
and symptoms, considering that calcium has distinct 
roles in various organs and tissues, including the central 
nervous system, heart, skeletal muscle, and kidneys 
(2,3,22). The severity of the symptoms depends on 
the duration and intensity of the hypocalcemia and on 
how fast the manifestations emerge (D). Classically, 
low serum calcium manifests acutely with paresthesias 
in the face or distal extremities, weakness, and 
muscle pain accompanied or not by increased levels 
of the enzyme creatine phosphokinase (CPK) (C) 
(86,87). Hypocalcemia is associated with increased 
neuromuscular excitability; therefore, symptoms such 
as carpopedal spasms, cramps, and muscle contraction 
are characteristic of this metabolic disorder. 
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On physical examination, the characteristic signs 
of hypocalcemia reflecting a status of neuromuscular 
excitability are Trousseau’s and Chvostek’s signs. The 
first is an involuntary contraction of the forearm muscles 
with flexion of the wrist and metacarpophalangeal joint, 
extension of the interphalangeal joints, and adduction of 
the thumb (“obstetrician’s hand” or carpopedal spasm) 
when the cuff of the sphygmomanometer is inflated 10 
to 20 mmHg above the systolic pressure for about 3 
minutes causing an occlusive pressure (88). Although 
this sign is very specific of hypocalcemia, it may also 
be present in up to 4% of the normal individuals (B). 
The Chvostek’s sign is characterized by an ipsilateral 
contraction of the muscles around the lips or other 
facial muscles triggered by the tapping of the facial 
nerve over its trajectory anterior to the ear (89). This 
signal may be also positive in up to 10% of the normal 
individuals (D).   
In severe cases, excessive muscle contraction may 
lead to spontaneous tetany or trigger generalized 
seizures, which may be the initial presentation of 
hypoparathyroidism (C) (90). In addition, acute and 
severe hypocalcemia can potentially lead to sudden 
dyspnea followed by laryngeal stridor, characterizing 
laryngospasm (91), or result in papilledema associated 
or not with increased intracranial pressure. All these 
situations are reversible with normalization of serum 
calcium levels (C) (92,93).
Since calcium plays a fundamental role in myocardial 
excitation and contraction, severe hypocalcemia triggers 
electrocardiographic changes such as prolongation of 
the QT interval, which may progress to ventricular 
fibrillation and cardiac arrest (C) (94). There have 
been reports of dilated cardiomyopathy with systolic 
dysfunction reversing after normalization of calcium 
levels (C) (95,96).
Some dermatological manifestations secondary 
to acute hypocalcemia have been reported, including 
piodermitis and acute generalized pustular psoriasis 
(psoriasis of von Zumbusch) (C) (97-99). The reason 
for the association between hypocalcemia and psoriasis, 
specifically, is the role of the intracellular calcium in 
regulating the proliferation and differentiation of 
keratinocytes (97-99).
In contrast to the manifestations in acute 
hypocalcemia, neuromuscular symptoms may be milder 
in chronic hypocalcemia (D) (2,3,22). Some chronic 
manifestations such as cataract and cerebral calcification 
will be discussed in the session dedicated to chronic 
complications (100-102). 
Hypocalcemia of long duration has been associated 
with psychiatric manifestations, such as mood changes, 
anxiety, depression, and, more rarely, hallucinations 
and psychotic episodes (C) (103). 
Other symptoms including tinnitus and dizziness 
have been reported in patients with hypocalcemia and 
cerebral calcification (C) (104). Nonspecific signs 
may be present, such as dry and rough skin, weak and 
brittle nails, and dry hair (105). Dental abnormalities, 
especially during childhood, such as delayed teeth 
eruption, dental hypoplasia, and enamel and tooth root 
defects, have also been reported (C) (106). 
Highlights SBEM: The most frequent symptoms 
of acute hypocalcemia are paresthesias, cramps, pain, 
and muscle weakness. In cases of severe hypocalcemia, 
seizures, tetany, papilledema, and laryngospasm 
may be included in the clinical manifestations. On 
physical examination, the presence of Trousseau’s 
and Chvostek’s signs suggest hypocalcemia. Chronic 
hypocalcemia may be asymptomatic (C). 
DIAGNOSIS
7. How is hypoparathyroidism diagnosed?
Although hypoparathyroidism is suspected on clinical 
grounds, its diagnosis is based on laboratory tests 
demonstrating inappropriately low PTH levels in the 
presence of hypocalcemia (A) (1-3,9,21). Of note, 
the definite calcium and PTH values for diagnosis of 
hypoparathyroidism have not been defined yet.
The diagnosis of hypoparathyroidism should 
take into account the presence of suggestive clinical 
manifestations, history of surgery or cervical irradiation, 
and factors that might suggest the etiology of the 
disease, such as concomitant autoimmune conditions 
or syndromic manifestations (2,20). The physical 
examination must include a careful inspection of the 
cervical region in search of signs of prior surgery and 
assessment of Chvostek’s and Trousseau’s signs (1-3).
The laboratory evaluation must include serum 
measurement of total calcium corrected for albumin, 
PTH, phosphorus, magnesium, creatinine, and 
25(OH)D, in addition to 24-hour urinary calcium (A) 
(1-3,9,21).
Some laboratory features of hypoparathyroidism 
are noteworthy. Although ionized calcium is the 
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physiologically active calcium fraction, its measurement 
requires standardized blood collection and pre-analytical 
care, both of which are not always followed. In clinical 
practice, the most reliable alternative to ionized calcium 
measurement is the determination of total calcium 
corrected for albumin, which is calculated by adding 
0.8 mg/dL for each 1.0 g/dL decrease in albumin level 
below 4.0 g/dL (6-9). The diagnosis of hypocalcemia 
is established in the presence of calcium levels below 
the normal range, but in hypoparathyroidism, the 
levels are usually below 7.5 mg/dL (C). In cases of 
rapid development, the symptoms may precede the 
hypocalcemia (C) (107).
The values of intact PTH are low or undetectable. 
In the presence of hypocalcemia, values below 
20 ng/mL are diagnostic of hypoparathyroidism (20). 
PTH measurement requires certain care with blood 
collection and storage (108).
Levels of phosphorus in chronic hypoparathyroidism 
are usually increased, but in the presence of concomitant 
hungry bone syndrome, they may be within the normal 
range or decreased. Measurement of magnesium levels 
is important to rule out functional hypoparathyroidism. 
The determination of serum creatinine and 25(OH)D 
levels are useful during follow-up. 
In the presence of a normal renal function, the 24-
hour urinary calcium reflects the nutritional intake of 
calcium. During follow-up, it is important to monitor 
the occurrence of hypercalciuria (urinary calcium greater 
than 4 mg/kg/day), due to the absence of PTH during 
treatment with calcium and vitamin D (A) (109,110). 
The etiologic diagnosis of nonsurgical 
hypoparathyroidism is challenging. So far, no 
autoantibody has been standardized for this purpose 
in clinical practice, although the determination of anti-
IFNω and anti-NALP5 has proven to be useful in this 
regard (111). The diagnosis of autosomal dominant 
hypocalcemia through molecular CaSR analysis is 
important during management of this condition to 
prevent nephrolithiasis/nephrocalcinosis (B) (111).
Highlights SBEM: Hypoparathyroidism is suspected 
on clinical grounds, but its diagnosis is based on 
laboratory tests indicating inappropriately low PTH 
levels in the presence of hypocalcemia (A). The patient’s 
laboratory evaluation must include total serum 
calcium corrected for albumin, PTH, phosphorus, 
magnesium, creatinine and 25-hydroxyvitamin D, in 
addition to 24-hour calciuria (A).
TREATMENT
8.  How should patients with hypoparathyroidism 
be treated? How should therapeutic failure with 
conventional treatment be defined?
Treatment of hypoparathyroidism is aimed at correcting 
hypocalcemia and hyperphosphatemia, reducing 
symptoms, and preventing chronic complications 
resulting from the disease or its treatment. To avoid 
long-term side effects, the goal of the treatment is to 
maintain the total calcium close to the lower normal 
range. Persistent hypomagnesemia after normalization 
of calcium levels must be corrected (112). Two 
different strategies may be used, depending on the 
rate of development of hypocalcemia and presence of 
symptoms (A). 
8.1 Treatment of acute hypocalcemia
Acute manifestations threatening the patients’ 
lives such as tetanic seizures, laryngospasm or 
bronchospasm, seizures, bradycardia, prolongation of 
the QT interval, or congestive heart failure, require 
urgent treatment with intravenous calcium (A) 
(1-3,7,20,21,107,112,113). The most used salt 
among us is 10% calcium gluconate, which contains 
approximately 90 mg of elemental calcium per 10 mL of 
solution. One to two ampoules should be diluted in 50 
to 100 mL of 0.9% saline solution (SS) or 5% glycosylated 
solution (GS) and administered slowly via intravenous 
infusion over 10 to 20 minutes (B). Rapid infusion 
may trigger cardiac arrhythmias and cause a severe 
inflammatory reaction in the venous path (phlebitis). 
Overflow may lead to calcification of local soft tissues, 
especially when serum phosphorus concentrations are 
increased. To preserve normocalcemia, a continuous 
infusion of elemental calcium 0.5 to 2.0 mg/kg of 
body weight/hour diluted in 5% GS may be required 
until the effect of the long-term oral medications on 
calcium levels becomes established (B). Serum calcium 
concentrations must be periodically monitored for 
titration of the infusion dose; the heart rhythm should 
also be monitored, especially in patients on digitalis 
(A) (1-3,7,20,21,107,112,113). 
8.2 Treatment of chronic hypocalcemia
Calcium concentrations must also be corrected in 
patients with slowly developing hypocalcemia (chronic), 
but intravenous calcium infusion is not required if the 
patient is mildly symptomatic or asymptomatic. 
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Maintenance of calcium concentrations in the long 
term has been achieved with the use of vitamin D or its 
active form, calcitriol, associated with oral calcium salts 
(A) (1-3,7,20,21,107,112,113). 
The conversion of 25(OH)D into its active 
metabolite (1,25(OH)2D or calcitriol) is catalyzed 
by the enzyme 1α-hydroxylase in renal tubular 
cells, usually stimulated by PTH and inhibited by 
hyperphosphatemia (11). Therefore, the production 
of 1,25(OH)2D is reduced in hypoparathyroidism. For 
this reason and due to a shorter half-life, treatment 
with oral calcitriol is preferable (B), although vitamin D 
(cholecalciferol or ergocalciferol) may also be used (B) 
(114). The effects of these hypercalcemic drugs arise 
mainly from their action on the absorption of calcium 
in the intestine, but when administered in excessive 
doses, they stimulate bone resorption and promote the 
release of calcium from the bone (A) (115). In severe 
PTH deficiency, calcium levels can only be normalized 
with calcitriol or high doses of vitamin D (C). With a 
long biological half-life (4 to 6 hours), calcitriol may 
be administered every 12 hours, and its initial doses 
range from 0.5 to 1.0 µg/day divided into at least 
two daily doses. Serum calcitriol peak is achieved 
4 to 6 hours after administration, and elevations 
in calcium levels may be observed 1 to 3 days after 
treatment initiation. The dose of calcitriol should be 
titrated according to calcium levels and varies among 
individuals, in some cases exceeding 2.0 µg/day (B) 
(1-3,7,20,21,107,112,113). High doses of vitamin D 
(ergocalciferol or cholecalciferol) may also be used to 
treat hypoparathyroidism and have often been used in 
the past when access to calcitriol was restricted. The 
effects of these agents in increasing calcium levels take 
longer (approximately ten days), and their biological 
half-life is 2 to 3 weeks. Since these doses are very 
high, situations of severe intoxication manifesting with 
hypercalcemia may occur in the long term and are 
usually very prolonged (A) (114). Due to that, there 
is a preference for the use of calcitriol, whose shorter 
half-life enables faster correction of calcium levels, 
both in cases of hypocalcemia as well as hypercalcemia 
secondary to intoxication (B). There is no evidence that 
the use of vitamin D supplementation doses associated 
with calcitriol is effective in controlling calcium when 
compared to calcitriol alone.
The use of oral calcium salts is essential in the 
treatment of hypocalcemia and has two objectives: 
to offer calcium for absorption by the intestinal cells 
under the effect of vitamin D, and to sequester radicals 
containing phosphorus present in the food, indirectly 
reducing phosphatemia (1-3). 
The most commonly used calcium salts are 
carbonate and citrate. Calcium carbonate has a larger 
amount of elemental calcium per gram of salt (40%) 
and a lower cost. However, the calcium requires gastric 
acidity to dissociate from the salt and be absorbed. 
In cases of achlorhydria, low acidity (use of proton 
pump inhibitors), or gastrectomy, calcium citrate is 
preferred despite a lower concentration of elemental 
calcium per gram of salt (21%) and a higher cost 
(113). Other calcium formulations may be used, 
such as lactogluconate and citrate malate, but their 
use has limited scientific evidence. The daily amount 
of required elemental calcium varies greatly among 
patients, from as little as 1 g to as much as 9 g (21), 
but most of patients can be well controlled with daily 
doses ranging from 1 to 3 g, divided in three times a 
day over meals (A) (1-3,7,20,21,107,112,113). Due 
to the absence of the phosphaturic PTH action, it is 
recommended to limit the amount of phosphates and 
calcium phosphate salts in the diet. For this reason, 
increased intake of dairy products, which are rich in 
calcium but have a high phosphorus content, should 
not be encouraged (D). 
The use of intestinal phosphate chelating agents 
may be rarely necessary, in addition to the use of 
calcium carbonate, which also performs this function 
(B) (1-3). Unfortunately, vitamin D derivatives do not 
fully replace the effects of PTH, so this treatment is not 
substitutive. An important PTH effect is an increase 
in tubular calcium reabsorption. When calcium levels 
are increased during vitamin D administration, the 
supply of calcium to the glomerular filtrate increases. 
Without the effect of PTH to induce tubular calcium 
reabsorption, hypercalciuria may occur and lead in the 
long term to complications such as nephrolithiasis, 
nephrocalcinosis, and renal insufficiency (A) 
(24,116,117). To correct hypercalciuria during 
hypoparathyroidism treatment, thiazide diuretics 
including chlorthalidone and hydrochlorothiazide may 
be used, although this approach has variable efficacy. 
The dose of hydrochlorothiazide varies between 25 to 
50 mg administered in one or two doses a day and the 
association with amiloride may help spare potassium, 
avoiding hypokalemia secondary to prolonged use of 
such diuretics (B) (1-3,7,20,21,107,112,113). 
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Magnesium has metabolic pathways very similar 
to those of calcium, and its level may decrease, 
especially in the occurrence of hypocalcemia. Usually, 
magnesium levels correct in parallel to those of calcium, 
but in some cases, supplementation with magnesium 
salts is required, particularly in hypoparathyroidism 
resulting from activating CaSR mutation (1-3,113). 
Commercially available magnesium pidolate has 
130 mg of elemental magnesium in each vial and the 
dose varies between 1 to 2 vials a day, but manipulated 
formulations may also be used. 
Treatment of hypoparathyroidism with calcium salts 
and vitamin D has some challenges. The success of the 
treatment depends on the patient ingesting several pills 
many times a day (B) (1-3,113). 
Some clinical situations may destabilize a well-
adjusted treatment or even hinder a proper control of 
calcium levels, including gastrointestinal infections, 
urgent hospitalizations, medications affecting the 
absorption of nutrients or other medications (orlistat, 
cholestyramine, and glucocorticoids, among others), 
as well as conditions associated with spontaneous 
malabsorption (inflammatory bowel disease, celiac 
disease, or malabsorption due to other causes) or 
iatrogenic (such as post-bariatric surgeries) and 
difficulties in the ingestion of medications by mouth, as 
seen in wide surgical resections due to laryngeal cancer 
(2,118-123). The metabolic control during pregnancy 
and lactation in patients with hypoparathyroidism will 
be discussed in Section 10. 
The use of PTH and its derivatives has been 
tested with some success in the treatment of 
hypoparathyroidism, and the use of PTH (1-84) has 
been approved by American and European agencies 
(FDA and EMA) and will be discussed in Section 9 
(124). Furthermore, perspectives point out to the 
use of allografts of macroencapsulated parathyroid 
cells, but studies in this regard are still in experimental 
phases (125).
Considering that a hypocalcemia emergency 
may be potentially lethal, patients with chronic 
hypoparathyroidism must carry an identification card 
indicating their diagnosis and treatment, in the case of 
emergency (D).
Highlights SBEM: Treatment of hypoparathy-
roidism aims at correcting hypocalcemia and hyper-
phosphatemia, reducing symptoms, and preventing 
chronic complications (B). The treatment goal is to 
maintain the patient asymptomatic, with total calcium 
levels close to the lower normal range, phosphorus 
levels close to the high normal range and 24-hour 
urinary calcium should be maintained within the 
normal range (below 300 mg/day) or below 4 mg/
kg/day. Treatment of acute hypocalcemia is aimed at 
controlling situations leading to imminent life threat 
and requires an intravenous infusion of calcium. The 
treatment of chronic hypocalcemia involves the use of 
active vitamin D and calcium salts (B).
9.  What evidence supports the use of PTH analogs in 
the treatment of hypoparathyroidism?
Hypoparathyroidism persists as the last classic hormone 
deficiency in which the conventional treatment is not 
done with replacement of the missing hormone (D) 
(1-3). There has been some accumulated experience 
with the use of PTH analogs since 1996, when 
Winer and cols. followed up adults treated with PTH 
(1-34,126-128) and studies with the duration of 3 years 
compared this type of treatment with the conventional 
one in children and adults (5-70 years). Serum calcium 
levels were more consistent, and no differences in 
urinary calcium were observed (B) (129,130). Studies 
with PTH (1-34) administered with a continuous 
infusion pump, compared with subcutaneous PTH 
(1-34) twice daily in adults and children, showed a more 
physiological control of serum calcium and reduction 
in urinary calcium (B) (131,132). It is important to 
highlight that PTH (1-34) is only approved for the 
treatment of osteoporosis in adults and for 18 to 24 
months, and has not been approved by regulatory 
agencies for the use in hypoparathyroidism.
In January 2015, the FDA approved the use of 
PTH (1-84) for the treatment of hypoparathyroidism. 
From a pharmacokinetic standpoint, this molecule 
has a longer half-life, which allows for a single daily 
application. Studies have shown that the dose of PTH 
(1-84) must be titrated between 25, 50, 75, and 
100 µg, thus enabling a reduction in the doses of calcium 
and vitamin D. Serum calcium must be monitored since 
episodes of hypercalcemia have been described, mostly 
asymptomatic, especially with the dose of 100 µg. In 
some cases, calcium and vitamin D supplements could 
be discontinued (B) (133-135). 
The REPLACE study (a double-blind, randomized, 
phase 3, placebo-controlled trial) has shown that 53% 
of the adult patients (18-85 years) treated with up to 
100 µg of PTH (1-84) were able to decrease by 50% 
Co
py
rig
ht
©
 A
E&
M
 a
ll r
ig
ht
s r
es
er
ve
d.
117
Diagnosis and treatment of hypoparathyroidism
Arch Endocrinol Metab. 2018;62/1 
their doses of calcium and vitamin D after 24 weeks 
compared with 2% in the placebo group (A) (136). 
A study with longer duration was published by Rubin 
and cols. with 33 patients followed up for six years with 
dose titration. There was a reduction in urinary calcium 
and maintenance of serum calcium, but a decrease in 
radial bone mineral density (BMD) in 33% (B) (124). 
The use of PTH analogs to treat hypoparathyroidism 
is promising, but several limiting aspects must be 
considered: these agents must be administered by 
injection, are very expensive, and have not been approved 
in Brazil yet (until November 2017). Additionally, 
their efficacy in preventing the emergence of chronic 
complications has not been proven so far, there are 
no studies in children, and the supplementation with 
calcium and vitamin D has not been entirely suspended 
in most patients. However, some situations have been 
considered as potential indicators of benefit from their 
use in the USA, where the drug has been approved 
(113,137).
Highlights SBEM: PTH analogues may be used 
to treat hypoparathyroidism in specific cases. As 
far, there is no evidence showing their effectiveness 
in preventing chronic complications in the long 
term (D).
10.  How should hypoparathyroidism be managed 
during pregnancy and lactation?
The unique physiological environment during 
pregnancy, determined by cardinal transient factors 
such as the presence of the placenta (which is equipped 
with an endocrine machinery) and the demand for 
building blocks for the development of fetal organs 
and tissues (including bone), challenge adaptations in 
mineral metabolism. First, we must call attention to 
prominent differences in the consequences of vitamin 
D and PTH deficiencies in pregnant woman and the 
fetus (138,139). 
Physiological adaptations during pregnancy 
and lactation affect the management of maternal 
hypoparathyroidism. Calcium absorption is facilitated 
during pregnancy by increased calcitriol synthesis 
and sensitivity, among other factors. At this phase, 
maternal PTH secretion is inhibited, but serum calcium 
corrected for albumin remains normal. In contrast, the 
action of the PTH-related protein (PTHrP) produced 
by the mammary gland tends to mobilize calcium from 
the skeleton during lactation (138,139).
Another important consideration in the 
management of hypoparathyroidism during pregnancy 
is the effect of hemodilution on serum albumin levels 
and circulating total calcium. Due to that, ionized 
calcium is the preferred control parameter and should 
be measured every 2-3 weeks. However, the technique 
to measure ionized calcium is very sensitive and requires 
rigid but often neglected pre-analytical protocols, 
leading to inaccurate results (140). In this context, the 
determination of total calcium corrected for albumin is 
an advisable alternative. 
Hypoparathyroidism is a risky condition affecting 
the maternal/neonatal survival (spontaneous abortion, 
stillbirth, and premature labor), and impairing fetal 
bone development. Hypocalcemia in pregnant women 
with poorly controlled hypoparathyroidism leads to fetal 
secondary hyperparathyroidism with devastating effects 
on fetal bone, expressed as bone demineralization 
and fractures. In this case, concomitant maternal 
hyperphosphatemia is an additional worsening factor 
(C) (138,139).
The literature about the management of 
hypoparathyroidism during pregnancy and lactation 
is scarce and mostly based on case reports without 
randomized controlled studies comparing optional 
therapies (2). Frequent evaluations are necessary to 
assess symptoms and serum levels of albumin-corrected 
total calcium. Circulating calcium levels must be 
maintained in the lower normal range. During lactation, 
serum calcium levels must be closely verified due to the 
production of PTHrP by the breast and increased bone 
resorption, while medication tapering usually becomes 
necessary (C) (141). 
Activated vitamin D analogs (calcitriol or 1 
α-calcidiol) are preferable, but when unavailable, 
pharmacological doses of D2 or D3 may be used. 
The occurrence of an alternate source (placental) of 
1,25(OH)2D and PTHrP during pregnancy indicate 
a potential need for lowering the medication dose. 
However, there is usually no need to reduce the doses 
of calcium and calcitriol in clinical practice. Indeed, the 
increased demand of calcium for skeletal mineralization 
in the last trimester increases the requirement of 
calcitriol to avoid hypocalcemia. In case reports, oral 
elemental calcium varies from 800 to 1,500 mg at the 
beginning of pregnancy to 2,000 to 3,200 mg in the 
third gestational trimester (C) (142,143). 
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During pregnancy, the daily recommended dose 
of calcitriol is between 0.25-3 µg. At the beginning of 
lactation, the dose has to be individually reduced to 
avoid hypercalcemia. After weaning, the woman usually 
resumes the medication dose used before pregnancy. 
Pediatricians must be advised about the management 
of maternal hypoparathyroidism during pregnancy. 
When maternal overtreatment results in hypercalcemia, 
which in turn suppresses fetal PTH secretion, neonatal 
hypocalcemia must be assessed. On the other hand, 
maternal hypocalcemia may lead to fetal secondary 
hyperparathyroidism and skeletal abnormalities.
The authors encourage the readers to review the 
insightful articles by Kovacs and cols. about mineral 
metabolism in this singular period of a woman’s life 
(138,139). 
Highlights SBEM: Treatment of hypoparathyroid-
ism during pregnancy and lactation requires special 
care and more frequent control for dose adjustment, 
which must be individualized (C).
COMPLICATIONS
11.  What are the chronic complications of 
hypoparathyroidism? How should they be 
monitored?
The chronic complications of hypoparathyroidism 
are associated with the progression of the disease 
and the implemented therapy and include clinical 
comorbidities of varying severity (D) (22). Since for 
many years hypoparathyroidism remained a neglected 
disease, data on the long-term complications of this 
condition are rare.
11.1 Renal manifestations
Renal complications arise from chronic hypocalcemia 
and hyperphosphatemia due to lost regulation of 
calcium and phosphorus metabolism (D) (144). 
Treatment with large amounts of calcium and active 
vitamin D (calcitriol) leads to hypercalciuria, in addition 
to increasing the intestinal absorption of phosphorus, 
intensifying the hyperphosphatemia and increased 
calcium-phosphorus product and predisposing to 
nephrolithiasis and nephrocalcinosis. In a study by 
Mitchell and cols. in patients with hypoparathyroidism, 
higher serum calcium levels were associated with 
higher urinary calcium values, prevalence of 38%, 
while lithiasis and nephrocalcinosis were observed 
in 31% of the patients. Renal function was decreased 
in 52% of the patients and was associated with age, 
disease duration, and proportion of time with relative 
hypercalcemia (A) (116). In a study by Lopes and 
cols., the prevalence of renal complications in patients 
with hypoparathyroidism was 25%; although the levels 
of urinary calcium were within the normal range in 
most of the cohort, the levels in the group with renal 
complications were higher (around 3.3 mg/kg/day) 
(24). Renal manifestations occur independently from 
the etiology of the hypoparathyroidism (34,27) and are 
already present at birth in children affected with this 
disorder (117).
Although it is unclear in the literature whether 
prophylactic measures can prevent renal impairment, 
measurement of urinary calcium and serum creatinine are 
recommended every six months. The 24-hour urinary 
calcium should be maintained within the normal range 
for gender (below 300 mg/day) (21,109) or below 
4 mg/kg/d (20,110). Periodic imaging evaluations 
of the kidney and urinary tract are not supported in 
the literature. However, based on the high prevalence 
of renal manifestations, both European and American 
consensus recommendations include periodic imaging 
evaluations (D) (2,20). 
11.2 Cardiovascular manifestations
Two studies with historical and controlled cohorts 
in patients with nonsurgical hypoparathyroidism 
and postsurgical hypoparathyroidism have addressed 
the occurrence of cardiovascular complications. 
Although the general mortality in these cohorts 
was not increased, ischemic heart disease, stroke, 
and arrhythmia were more frequent in patients with 
nonsurgical hypoparathyroidism compared with the 
general population (A) (34). These complications 
should be individually monitored, and no established 
routine has been recommended.
11.3 Ocular manifestations
Epidemiological studies have shown that patients 
with nonsurgical hypoparathyroidism have a four-
fold increased risk and earlier onset of cataract when 
compared with the general population (A) (145). 
Annual clinical monitoring and metabolic control are 
recommended, despite the lack of studies confirming 
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an advantage of routine assessment in patients with 
hypoparathyroidism (D) (2). 
11.4 Neuropsychiatric manifestations 
Chronic complications of hypoparathyroidism 
affect the central nervous system and include cerebral 
calcifications, decreased seizure threshold, seizures, 
depression, and decreased quality of life (146). 
Cerebral calcifications vary in prevalence from 12% 
to 74% and are associated with the duration of the 
hypocalcemia (A) (103). Regardless of the etiology 
of the hypoparathyroidism, the occurrence of seizures 
is frequent and associated with a greater risk of 
hospitalization (A) (34,145). Therefore, determination 
of serum calcium is recommended during the etiological 
investigation of all patients with epilepsy (D).
Decreased quality of life is a common and important 
chronic complication of hypoparathyroidism and is 
associated with a multifactorial etiology. Although 
undervalued, studies report that decreased quality 
of life affects 32% to 65% of the patients with 
hypoparathyroidism (A) (34,103). Physical complaints 
(muscle spasms, decreased muscle strength, fatigue, 
myalgia, and paresthesia), cognitive symptoms (“brain 
fog” and difficult concentration), and depression and/
or anxiety are associated with decreased quality of 
life (D) (22). Depression and affective disorders are 
twice as frequent in postsurgical hypoparathyroidism 
and are associated with a feeling of poor health (A) 
(147). In nonsurgical hypoparathyroidism, there is a 
higher risk of hospitalization due to psychiatric diseases 
and a tendency to depression (A) (145). Traditional 
treatment of hypoparathyroidism is unable to prevent 
these manifestations (B) (18), and results obtained 
with PTH replacement show discrepancies between 
studies (B) (148,149).
11.5 Musculoskeletal manifestations 
The absence of PTH leads to decreased remodeling 
in both trabecular and cortical bone and a consequent 
increase in BMD. Peripheral quantitative computed 
tomography shows increased cortical and trabecular 
volume and decreased cortical porosity, without 
evidence of changes in bone strength (A) (150). 
Histomorphometry shows increased trabecular volume 
and width, with the maintenance of the trabecular 
number and spacing, decreased bone formation, and 
a lower bone resorption rate, which indicates a deep 
reduction in bone turnover rate in hypoparathyroidism 
(A) (151,152). Retrospective epidemiological 
studies have shown conflicting results concerning 
fractures of the superior limbs, showing a lower risk 
of fracture of the proximal humerus in postsurgical 
hypoparathyroidism and increased risk of fracture of 
the forearm in nonsurgical hypoparathyroidism (A) 
(34,145). The risk of fractures, in general, has been 
described as comparable to that in control populations 
(34,145). A pioneer prospective study with radiological 
assessment of vertebral fractures has shown increased 
morphometric fractures in women with postsurgical 
hypoparathyroidism (B) (153), a finding confirmed 
by other authors (154). Monitoring of bone mass 
using dual-energy X-ray absorptiometry (DXA) has 
little value during long-term follow-up of patients 
with hypoparathyroidism, noting that the BMD tends 
to increase with the duration of the disease (155). 
With the recent findings of a higher prevalence of 
morphometric vertebral fractures in patients with 
hypoparathyroidism, periodic radiologic monitoring of 
the spine is recommended in patients at risk. 
Highlights SBEM: Chronic complications of hypo-
parathyroidism are associated with the progression of 
the disease and its treatment, and include renal mani-
festations (hypercalciuria, nephrocalcinosis, nephro-
lithiasis, and renal insufficiency), cataract, cerebral 
calcifications, cognitive and affective manifestations, 
changes in quality of life, vertebral fractures, and in-
creased cardiovascular risk (A). Periodic monitoring 
of such complications is recommended and should be 
individualized (D).
CONCLUSIONS
Hypoparathyroidism is a neglected disease, and the 
scarcity of data regarding this condition restricts 
potential recommendations for its ideal management. 
The most common etiology of hypoparathyroidism is 
the surgical resection of the parathyroids and, therefore, 
the risk of postsurgical hypoparathyroidism should 
always be considered when thyroid and parathyroid 
surgeries are recommended, and the extent of these 
procedures is planned. From a surgical point of view, the 
maintenance of intact parathyroids in place is the most 
important factor in preventing hypoparathyroidism.
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Acute hypocalcemia is associated with frequent 
symptoms including paresthesias, cramps, pain, and 
muscle weakness, seizures, tetany, and laryngospasm, 
while chronic hypocalcemia may present with fewer 
manifestations. Hypoparathyroidism is suspected on 
clinical grounds but is diagnosed based on laboratory 
tests indicating inappropriately low PTH levels in the 
presence of hypocalcemia. 
The treatment of hypoparathyroidism is focused 
on correcting hypocalcemia and hyperphosphatemia, 
reducing symptoms, and preventing chronic 
complications. The treatment goal is to maintain 
the patient asymptomatic with a total calcium level 
close to the lower limit of the normal range, with the 
administration of active vitamin D and calcium salts. 
Special situations such as pregnancy and lactation 
require frequent and individualized monitoring.
The chronic complications of hypoparathyroidism 
are related to the disease progression and its treatment 
and include renal, ocular, cardiovascular, bone, and 
neuropsychiatric manifestations. Monitoring these 
complications is recommended. More studies are 
needed to evaluate their progression and response to 
treatment in order to improve the management of 
hypoparathyroidism.
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